In last trading session, 4D Molecular Therapeutics Inc (NASDAQ:FDMT) saw 1.01 million shares changing hands with its beta currently measuring 2.88. Company’s recent per share price level of $3.28 trading at $0.29 or 9.70% at ring of the bell on the day assigns it a market valuation of $151.87M. That closing price of FDMT’s stock is at a discount of -804.27% from its 52-week high price of $29.66 and is indicating a premium of 12.5% from its 52-week low price of $2.87. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.86 million shares which gives us an average trading volume of 816.41K if we extend that period to 3-months.
For 4D Molecular Therapeutics Inc (FDMT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.75. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
4D Molecular Therapeutics Inc (NASDAQ:FDMT) trade information
Upright in the green during last session for gaining 9.70%, in the last five days FDMT remained trading in the red while hitting it’s week-highest on Thursday, 03/27/25 when the stock touched $3.28 price level, adding 11.11% to its value on the day. 4D Molecular Therapeutics Inc’s shares saw a change of -41.11% in year-to-date performance and have moved -9.14% in past 5-day. 4D Molecular Therapeutics Inc (NASDAQ:FDMT) showed a performance of -17.38% in past 30-days. Number of shares sold short was 5.03 million shares which calculate 7.4 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 6 to the stock, which implies a rise of 45.33% to its current value. Analysts have been projecting 6 as a low price target for the stock while placing it at a high target of 6. It follows that stock’s current price would drop -82.93% in reaching the projected high whereas dropping to the targeted low would mean a loss of -82.93% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -9.89% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -20.38% while estimates for its earnings growth in next 5 years are of -4.47%.
4D Molecular Therapeutics Inc (NASDAQ:FDMT)’s Major holders
Insiders are in possession of 3.89% of company’s total shares while institution are holding 103.16 percent of that, with stock having share float percentage of 107.33%. Investors also watch the number of corporate investors in a company very closely, which is 103.16% institutions for 4D Molecular Therapeutics Inc that are currently holding shares of the company. RA CAPITAL MANAGEMENT, L.P. is the top institutional holder at FDMT for having 5.1 million shares of worth $107.01 million. And as of 2024-06-30, it was holding 9.2221 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 4.9 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.8579 of outstanding shares, having a total worth of $102.79 million.
